Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001307854 | SCV001497282 | uncertain significance | Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations | 2024-01-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 198 of the TREX1 protein (p.Glu198Lys). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individual(s) with Aicardi-Goutieres Syndrome and Sjogren’s syndrome (PMID: 20131292, 24224166). ClinVar contains an entry for this variant (Variation ID: 1010253). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002543212 | SCV003699538 | uncertain significance | Inborn genetic diseases | 2022-05-10 | criteria provided, single submitter | clinical testing | The c.592G>A (p.E198K) alteration is located in exon 2 (coding exon 1) of the TREX1 gene. This alteration results from a G to A substitution at nucleotide position 592, causing the glutamic acid (E) at amino acid position 198 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV003135949 | SCV003807844 | uncertain significance | Aicardi-Goutieres syndrome 1 | 2022-06-07 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS3 supporting, PS4 supporting, PM2 moderated, PP3 supporting |